References
- Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998; 135: 825–32
- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Eng J Med. 2002; 347: 161–7
- Poole-Wilson PA. Who are the enemies? Lack of oxygen. Eur Heart J. 2002; 4(Suppl.G)15–9
- Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82–91
- Kwan G, Isaksom SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol. 2007; 49: 1186–92
- Singh M, Reeder GS, Jacobsen SJ, Weston S, Killian J, Roger VL. Scores for post-myocardial infarction risk stratification in the community. Circulation 2002; 106: 2309–14
- Granger CB, Goldberg RJ, Dabbous O, Pieper KJ, Eagle KA, Cannon CP, et al. Predictors of hospital mortality with global registry of acute coronary events. Arch Intern Med. 2003; 163: 2345–53
- Cockcroft DW, Gault MH. Predictors of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41
- Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactiveamino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol. 1997; 47: 287–96
- van Kimmenade RJ, Januzzi JL, Bakker JA, et al. Renal clearance of B type natriuretic peptide and amino terminal pro-B-type natriuretic peptide: a mechanism study of hypertensive subjects. J Am Coll Cardiol. 2009; 53: 884–90
- Haug C, Metzele A, Steffgen J, Kochs M, Hombach V, Grunert A. Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Clin Invest. 1994; 72: 30–4
- Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J. 2005; 149: 744–50
- Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggiani AP, et al. N-terminal Pro-Brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128–34
- Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005; 26: 234–40
- Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2004; 25: 859–66
- Grabowski M, Filipiak KJ, Malek LA, Karpinski G, Huczek Z, Stolerz P, et al. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated by primary angioplasty. Int J Cardiol. 2007; 115: 386–90
- Jarai R, Iordanova N, Jarai R, et al. Prediction of clinical outcome in patients with non-ST-segment elevation acute coronary syndrome using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien Klin Wochenschr. 2007; 119(21–22)626–32
- Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008; 94: 40–3
- James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol. 2006; 97: 167–72
- Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PN, Morrow DA, et al. Association of elevated B-type natriuretic peptide levels with angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004; 44: 564–8
- Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmit-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin 2 and diastolic fiber length. Circulation 2000; 102: 3074–9
- Goetze JP, Christofferson C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003; 17: 1105–10
- Heeschen C, Hamm CW, Mitrovic V, Lantelme N, White HD. N-terminal Pro-B-type natriuretic peptide levels for dynamic risk stratification in patients with acute coronary syndromes. Circulation 2004; 110: 3206–12